List view / Grid view

Jason Fontenot (Sangamo Therapeutics)

 

article

Tackling immune-mediated disease with CAR Tregs

Here, Jason Fontenot, Chief Scientific Officer of Sangamo Therapeutics, discusses…

20 October 2022 | By

Here, Jason Fontenot, Chief Scientific Officer of Sangamo Therapeutics, discusses with EPR’s Hannah Balfour how the industry is developing chimeric antigen receptor (CAR) T regulatory cells (Tregs) as a potentially paradigm-shifting therapeutic option for conditions driven by the immune system, such as autoimmunity and transplant rejection.